Shares of Exelixis (NASDAQ:EXEL) have received an average recommendation of “Hold” from the sixteen ratings firms that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $34.63.
A number of research analysts have recently commented on EXEL shares. Cann upgraded Exelixis from a “market perform” rating to an “outperform” rating and set a $40.00 price target for the company in a report on Tuesday, February 27th. They noted that the move was a valuation call. Stifel Nicolaus upped their price target on Exelixis from $29.00 to $30.00 and gave the stock a “hold” rating in a report on Tuesday, February 27th. Zacks Investment Research upgraded Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price target for the company in a report on Tuesday, January 2nd. William Blair reiterated an “outperform” rating on shares of Exelixis in a report on Monday, February 12th. Finally, BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a report on Thursday, January 25th.
Shares of Exelixis stock opened at $21.09 on Friday. The company has a market cap of $6,548.39, a price-to-earnings ratio of 41.35 and a beta of 2.10. Exelixis has a 12-month low of $18.03 and a 12-month high of $32.50.
Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Monday, February 26th. The biotechnology company reported $0.12 EPS for the quarter, hitting analysts’ consensus estimates of $0.12. Exelixis had a return on equity of 81.05% and a net margin of 34.08%. The company had revenue of $120.10 million during the quarter, compared to analyst estimates of $120.25 million. During the same period in the previous year, the company earned $0.12 earnings per share. The company’s quarterly revenue was up 54.8% compared to the same quarter last year. equities analysts forecast that Exelixis will post 0.54 EPS for the current fiscal year.
In related news, Director Vincent T. Marchesi sold 15,000 shares of the company’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $24.73, for a total value of $370,950.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lance Willsey sold 30,000 shares of the company’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $23.91, for a total value of $717,300.00. Following the completion of the transaction, the director now owns 483,273 shares of the company’s stock, valued at $11,555,057.43. The disclosure for this sale can be found here. Insiders sold 120,029 shares of company stock valued at $3,158,287 over the last 90 days. 5.10% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of EXEL. Sigma Planning Corp acquired a new position in shares of Exelixis in the fourth quarter valued at $208,000. American International Group Inc. acquired a new position in shares of Exelixis in the fourth quarter valued at $208,000. Klingenstein Fields & Co. LLC acquired a new position in shares of Exelixis in the fourth quarter valued at $213,000. Raymond James Financial Services Advisors Inc. acquired a new position in shares of Exelixis in the third quarter valued at $236,000. Finally, Mackenzie Financial Corp raised its stake in shares of Exelixis by 24.1% in the third quarter. Mackenzie Financial Corp now owns 10,116 shares of the biotechnology company’s stock valued at $245,000 after purchasing an additional 1,963 shares in the last quarter. Institutional investors and hedge funds own 80.50% of the company’s stock.
WARNING: “Exelixis (EXEL) Receives Average Rating of “Hold” from Analysts” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/exelixis-exel-receives-average-rating-of-hold-from-analysts.html.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.